GZGuangshuai Zhang

Guangshuai Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Guangshuai Zhang has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • Bingyang Liu

    Wuya College of Innovation, Shenyang Pharmaceutical University, No. 103, Wenhua Road, Shenyang 110016, China

    1 shared publication
  • Dandan Song

    Wuya College of Innovation, Shenyang Pharmaceutical University, No. 103, Wenhua Road, Shenyang 110016, China

    1 shared publication
  • Mo Li

    Liaoning Institute for Drug Control, No. 7 Chongshan West Road, Shenyang 110016, China

    1 shared publication
  • Qiang Fu

    Wuya College of Innovation, Shenyang Pharmaceutical University, No. 103, Wenhua Road, Shenyang 110016, China

    1 shared publication
  • Ruilong Ma

    Wuya College of Innovation, Shenyang Pharmaceutical University, No. 103, Wenhua Road, Shenyang 110016, China

    1 shared publication
  • Zhonggui He

    Wuya College of Innovation, Shenyang Pharmaceutical University, No. 103, Wenhua Road, Shenyang 110016, China

    1 shared publication

Latest Publications

  • Artificial mucus layer formed in response to ROS for the oral treatment of inflammatory bowel disease

    by Guangshuai Zhang, Dandan Song, Ruilong Ma, Mo Li, Bingyang Liu, Zhonggui He, Qiang Fu

    The artificial mucus layer, such as hydrogels, used to repair the damaged intestinal barrier, is a promising treatment for inflammatory bowel disease (IBD). However, the currently reported hydrogel-based artificial barriers are administered via rectal injection, causing unnecessary discomfort to patients. Herein, we report an oral hydrogel precursor solution based on thiol-modified hyaluronic acid (HASH). Owing to the reactive oxygen species (ROS)–responsive gelling behavior, our precursor solution formed an artificial mucus coating over the inflamed regions of the intestines, blocking microbial invasion and reducing abnormally activated immune responses. Notably, HASH also modulated the gut microbiota, including increasing the diversity and enhancing the abundance of short-chain fatty acid–associated bacteria, which play a key role in gut homeostasis. We believe that the ROS-responsive artificial mucus layer is a promising strategy for the oral treatment of IBD.